Eptifibatide: A pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes

PharmacoEconomics

Volumn 21, Issue 12, 2003, Pages 885-912

  Plosker, Greg L ^a   Ibbotson, Tim ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO;

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DATA ANALYSIS; DRUG EFFICACY; DRUG TOLERABILITY; HEALTH SURVEY; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; PHARMACOECONOMICS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; HUMANS; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; QUALITY OF LIFE;

EID: 0041854237     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321120-00005     Document Type: Review

References (85)

1. Goa KL, Noble S. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs 1999 Mar; 57 (3): 439-62
2. Integrilin (eptifibatide) injection prescribing information. San Francisco (CA): COR Therapeutics Inc., 2001
3. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina) [online]. Available from URL: http://www.acc.org [Accessed 2002 Jun 4]
4. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: summary article. Circulation 2002 Oct 1, 1893-900
5. Dery JP, O'Shea JC, Tcheng JE. Eptifibatide in percutaneous coronary intervention. A review. Minerva Cardioangiol 2002 Oct; 50 (5): 531-46
6. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. PURSUIT Trial Investigators. N Engl J Med 1998; 339: 436-43
7. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. ESPRIT Investigators. Lancet 2000 Dec 16; 356 (9247): 2037-44
8. Popma JJ, Ohman EM, Weitz J, et al. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest 2001; 119 Suppl.: 321S-36S
9. Belli G, Ellis SG, Topol EJ. Stenting for ischemic heart disease. Prog Cardiovasc Dis 1997; 40: 159-82
10. Truong KM, Amankwa K, Kucukarslan S. Platelet glycoprotein IIb/IIIa-receptor inhibitors in patients with acute coronary syndromes or undergoing percutaneous coronary interventions: a review. Clin Ther 2001 Aug; 23 (8): 1145-65; discussion 1129
11. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 2000 Sep 27; 284 (12): 1549-58
12. Yusuf S, Flather M, Pogue J, et al. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation: OASIS Registry Investigators. Lancet 1998; 352: 507-14
13. American Heart Association. 2001 Heart and Stroke Statistical Update. Heart attack and angina statistics [online]. Available from URL: http://www.americanheart.org [Accessed 2002 Jun 4]
14. Cannon CP. Glycoprotein IIb/IIIa inhibitors in unstable angina and non-ST segment elevation myocardial infarction. Coron Artery Dis 1999; 10 (8): 561-6
15. McElwee NE, Johnson ER. Potential economic impact of glycoprotein IIb-IIIa inhibitors in improving outcomes of patients with acute ischemic coronary syndromes. Am J Cardiol 1997; 80 (4 A): 39B-43B
16. Eisenstein EL, Shaw LK, Anstrom KJ, et al. Assessing the clinical and economic burden of coronary artery disease: 1986-1998. Med Care 2001 Aug; 39 (8): 824-35
17. Cohen DJ, O'Shea JC, Pacchiana CM, et al. In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin. Am J Cardiol 2002 Jan 1; 89 (1): 61-4
18. McKay RG, Boden WE. Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non-ST-segment elevation acute coronary syndromes: results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials. Curr Opin Cardiol 2001 Nov; 16 (6): 364-9
19. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-9
20. Jarvis B, Simpson K. Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs 2000 Aug; 60 (2): 347-77
21. Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol 2000 Apr; 35 (5): 1103-15
22. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. The IMPACT Investigators. Lancet 1997; 349: 1422-8
23. Phillips DR, Teng W, Arfsten A, et al. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997; 96: 1488-94
24. O'Shea JC, Buller CE, Cantor WJ, et al. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 2002 Feb 6; 287 (5): 618-21
25. O'Shea JC, Hafley GE, Greenberg S, et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial. JAMA 2001 May 16; 285 (19): 2468-73
26. Blankenship JC, Tasissa G, O'Shea JC, et al. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPIRIT trial. J Am Coll Cardiol 2001 Sep; 38: 653-8
27. Cantor WJ, Hellkamp AS, O'Shea JC, et al. Bailout platelet GP IIb/IIIa inhibition in coronary stent implantation: observations from the ESPRIT trial [abstract no. 885-3]. J Am Coll Cardiol 2001 Feb; 37 Suppl. A: 84A
28. Chandler B, O'Shea JC, Greenberg S, et al. Robust benefit of platelet GP IIb/IIIa inhibition with eptifibatide in patients undergoing stent PCI with hot or cold presentation. J Am Coll Cardiol 2001 Feb; 37 Suppl. A: 76A-7A
29. Fernandes LS, Tcheng JE, Kleiman NS, et al. Eptifibatide is as effective in women as in men: lessons from the ESPRIT trial [abstract no. 3790]. Circulation 2000 Oct 31; 102 Suppl.: 785
30. Gibson CM, Cohen DJ, Cohen EA, et al. Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Am J Cardiol 2001 Jun 1; 87 (11): 1293-5
31. Labinaz M, Madan M, McGuire DK, et al. Effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, among diabetic patients following coronary stenting: results from ESPRIT [abstract no. 3215]. Circulation 2000 Oct 31; 102 Suppl.: 665
32. O'Shea JC, Lorenz TJ, Joseph D, et al. Robust benefit of glycoprotein IIb/IIIa inhibition with eptifibatide in patients undergoing stent percutaneous coronary intervention with positive cardiac markers at baseline [abstract no. TCT-30]. Am J Cardiol 2000 Oct 16; 86: 13i-4i
33. O'Shea JC, Cohen EA, Buller CEH, et al. Predictors of improvement in clinical outcomes of non-acute coronary stenting in the Esprit trial. Circulation 2000 Oct 31; 102 Suppl.: II-665
34. O'Shea JC, Mann T, Hellkamp A, et al. Fewer bleeding complications with comparable efficacy with the transradial approach in coronary artery stenting: an analysis of the ESPRIT trial [abstract no. 1123-1129]. J Am Coll Cardiol 2001 Feb; 37 Suppl. A: 33
35. Hillegass WB, Newman AR, Raco DL. Economic issues in glycoprotein IIb/IIIa receptor therapy. Am Heart J 1999 Jul; 138 (1 Pt 2): S24-32
36. Dyke CM, Bhatia D, Lorenz TJ, et al. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy. Ann Thorac Surg 2000 Sep; 70 (3): 866-71; discussion 871-2
37. Akkerhuis KM, Deckers JW, Boersma E, et al. Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT. Eur Heart J 2000 Mar; 21 (5): 371-81
38. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients. Circulation 2000 Jun 6; 101: 2557-67
39. Cohen MG, Pacchiana CM, Corbalán R, et al. Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. Am Heart J 2001 Mar; 141: 391-401
40. Greenbaum AB, Harrington RA, Hudson MP, et al. Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. J Am Coll Cardiol 2001; 37 (2): 492-8
41. Hasdai D, Holmes Jr DR, Criger DA, et al. Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide. PURSUIT trial investigators. Am Heart J 2000 Mar; 139 (3): 454-60
42. Kleiman NS, Lincoff AM, Flaker GC, et al. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes. Circulation 2000; 101 (7): 751-7
43. Labinaz M, Kilaru R, Pieper K, et al. Outcomes of patients with acute coronary syndromes and prior coronary artery bypass grafting: results from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation 2002 Jan 22; 105 (3): 322-7
44. Lauer MA, Houghtaling PL, Peterson JG, et al. Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation 2001 Dec 4; 104 (23): 2772-7
45. Lincoff AM, Harrington RA, Califf RM, et al. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition: insights from the Platelet Glycoprotein IIb/IIIa in Unstable Angina. Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. Circulation 2000; 102 (10): 1093-100
46. Mahaffey KW, Harrington RA, Simoons ML, et al. Stroke in patients with acute coronary syndromes: incidence and outcomes in the Platelet Glycoprotein IIb/IIIa in Unstable Angina Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. PURSUIT Investigators. Circulation 1999 May 11; 99 (18): 2371-7
47. Marso SP, Bhatt DL, Roe MT, et al. Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. PURSUIT Investigators. Circulation 2000 Dec 12; 102 (24): 2952-8
48. McClure MW, Berkowitz SD, Sparapani R, et al. Clinical signifcance of thrombocytopenia during a non-ST-elevation acute coronary syndrome: the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. Circulation 1999 Jun 8; 99 (22): 2892-900
49. Peterson JG, Topol EJ, Roe MT, et al. Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol 2001 Mar 1; 87 (5): 532-6
50. Akkerhuis M, Boersma E, Harrington RA, et al. Eptifibatide protects against adverse cardiac complications both before and during percutaneous intervention in patients with acute coronary syndromes without ST-elevation [abstract no. 1068-53]. J Am Coll Cardiol 1999 Feb; 33 Suppl. A: 40A
51. Berdan LG, Lorenz TJ, Hochman JS. Eptifibatide reduces the incidence of coronary events in patients with non-ST-elevation acute coronary syndromes undergoing early cardiac catheterization and revascularization regardless of patient gender [abstract no. 1037-104]. J Am Coll Cardiol 2000 Feb; 35 Suppl. A: 343A (plus poster)
52. Harrington RA, Lincoff MA, Berdan LG, et al. Maintenance of clinical benefit at six-months in patients treated with the platelet glycoprotein IIb/IIIa inhibitor eptifibatide versus placebo during an acute ischemic coronary event [abstract no. 1886]. Circulation 1998; 98: I-359
53. Alexander JH, Sparapani RA, Mahaffey KW, et al. Eptifibatide reduces the size and incidence of myocardial infarction in patients with non-ST-elevation acute coronary syndromes [abstract no. 1032-133]. J Am Coll Cardiol 1999; 33 Suppl. A: 331A
54. Cohen DJ, Cosgrove RS, Berezin RH, et al. Cost-effectiveness of eptifibatide in patients undergoing planned coronary stenting: results from the ESPRIT trial [abstract no. 893153]. Circulation 2001 Oct 23; 104 Suppl. II (17): II-386
55. Data on file, Schering ACS, Kenilworth, NJ, USA. 2003
56. Brown RE, Henderson RA, Koster D, et al. Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. Platelet IIa/IIb in Unstable Angina: Receptor Suppression Using Integrilin Therapy. Eur Heart J 2002 Jan; 23 (1): 50-8
57. Mark DB, Harrington RA, Lincoff AM, et al. Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes. Circulation 2000 Feb 1; 101 (4): 366-71
58. Brown R, Armstrong P. Cost effectiveness in Canada of eptifibatide treatment for acute coronary syndrome patients using PURSUIT subgroup analysis. Can. J. Cardiol. 2003 Feb; 19 (2): 161-6
59. Sridhar K, Gwadry F, Kidwai B, et al. Decision analysis model of abciximab, eptifibatide or standard therapy in elective stent placement: a Canadian perspective. Value Health 2001; 4: 108
60. PRICE Investigators. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) trial. Am Heart J 2001 Mar; 141 (3): 402-9
61. Lage MJ, Barber BL, McCollam PL, et al. Impact of abciximab versus eptifibatide on length of hospital stay for PCI patients. Catheter Cardiovasc Interv 2001; 53 (3): 296-303
62. McCollam PL, Luzadis R. Hospital charges in common percutaneous coronary intervention patients receiving abciximab vs eptifibatide [absract no. 189]. Pharmacotherapy 2001 Oct; 21: 1284
63. Rose L, Hoying M, Przytulski B. A drug use evaluation of abciximab and eptifibatide in a community hospital. PT 2000; 25 (7): 360-6
64. Wong DH. Comparison of eptifibatide and abciximab with decision analysis. Am J Health Syst Pharm 2001 Aug 1; 58 (15): 1432-6
65. Schweiger MJ, Changezi HU, Naglieri-Prescod D, et al. Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary intervention. Clin Ther 2003; 25: 225-34
66. Henderson RA, Brown R. The costs of routine eptifibatide use in acute coronary syndromes in Western Europe: an economic substudy of the PURSUIT trial. Eur Heart J Suppls 1999 Aug; 1 Suppl. N: N35-41
67. Villar FA, Botella FA. An economic evaluation of eptifibatide [in Spanish]. Rev Esp Cardiol 2001 Feb; 54 (2): 169-74
68. Brown RE, Hutton J, Henderson R. Cost-effectiveness of eptifibatide in the UK based on PURSUIT trial [abstract no. PCV9]. Value Health 2001 Nov-2001 31; 4: 491
69. Kent DM, Ruthazer R, Beshansky JR, et al. Effectiveness and cost-effectiveness of eptifibatide in individual patients with acute cardiac ischemia: the importance of risk stratification [abstract no. CV2]. Value Health 2000; 3: 295
70. Szucs TD, Schwenkglenks M, Berger K, et al. Costs and cost-effectiveness of eptifibatide in the treatment of coronary ischemic syndromes. An analysis based on the PURSUIT study [in German]. Z Kardiol 2003 Mar; 92 (3): 236-44
71. Bank of Canada - Exchange rates results [online]. Available from URL: http://www.bank-banque-canada.ca [Accessed 2002 Jun 20]
72. Shahriar J, Shaw JW, Malone D. Cost-effectiveness analysis of abciximab, eptifibatide, and tirofiban in patients with coronary syndromes [abstract no. PCV21 plus poster]. Value Health 2001; 4: 103
73. Cupples ME, Dempster M. Improving quality of life for patients with angina pectoris: a team approach to disease management. Dis Manage Health Outcomes 2001; 9 (9): 473-81
74. Bliven BD, Green CP, Spertus JA. Review of available instruments and methods for assessing quality of life in anti-anginal trials. Drugs Aging 1998 Oct; 13: 311-20
75. Gandjour A, Lauterbach KW. Review of quality-of-life evaluations in patients with angina pectoris. Pharmacoeconomics 1999 Aug; 16 (2): 141-52
76. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000 Apr 29; 320: 1197-200
77. Zhou X-H, Melfi CA, Hui SL. Methods for comparing cost data. Ann Intern Med 1997; 127 (8 Pt 2): 752-6
78. Laskey WK, Williams DO, Vlachos HA, et al. Changes in the practice of percutaneous coronary intervention: a comparison of enrollment waves in the National Heart, Lung, and Blood Institute (NHLBI) Dynamic Registry. Am J Cardiol 2001; 87: 964-9
79. Goldman L, Garber AM, Grover SA, et al. Task force 6. Cost effectiveness of assessment and management of risk factors. J Am Coll Cardiol 1996; 27 (5): 964-1047
80. Lindholm L, Hallgren C-G, Boman K, et al. Cost-effectiveness analysis with defined budget: how to distribute resources for the prevention of cardiovascular disease? Health Policy 1999; 48: 155-70
81. Chapman RH, Stone PW, Sandberg EA, et al. A comprehensive league table of cost-utility ratios and a sub-table of "panel-worthy" studies. Med Decis Making 2000; 20: 451-67
82. Mason J, Drummond M, Torrance G. Some guidelines on the use of cost effectiveness league tables. BMJ 1993 Feb 27; 306: 570-2
83. Drummond MF, O'Brien BJ, Stoddart GL, et al. Presentation and use of economic evaluation results (chapter 9). In: Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997: 265-92
84. Drummond M, Torrance G, Mason J. Cost-effectiveness league tables: more harm than good? Soc Sci Med 1993; 37 (1): 33-40
85. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992; 146 (4): 473-81